Likewise, the phase II AVATAR trial assessed the continuation of CDK 4/6 inhibitors plus aromatase inhibitors in 32 oligoprogressive luminal BC patients undergoing SBRT among which 71 % had bone-only metastases. The gene discussed is CYP19A1; the disease is breast cancer.